Drug-induced apoptosis in yeast  by Almeida, B. et al.
Available online at www.sciencedirect.com
Biochimica et Biophysica Acta 1783 (2008) 1436–1448
www.elsevier.com/locate/bbamcrReview
Drug-induced apoptosis in yeast
B. Almeida, A. Silva, A. Mesquita, B. Sampaio-Marques, F. Rodrigues, P. Ludovico ⁎
Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal
Received 31 October 2007; received in revised form 21 December 2007; accepted 7 January 2008
Available online 17 January 2008Abstract
In order to alter the impact of diseases on human society, drug development has been one of the most invested research fields. Nowadays,
cancer and infectious diseases are leading targets for the design of effective drugs, in which the primary mechanism of action relies on the
modulation of programmed cell death (PCD). Due to the high degree of conservation of basic cellular processes between yeast and higher
eukaryotes, and to the existence of an ancestral PCD machinery in yeast, yeasts are an attractive tool for the study of affected pathways that give
insights into the mode of action of both antitumour and antifungal drugs. Therefore, we covered some of the leading reports on drug-induced
apoptosis in yeast, revealing that in common with mammalian cells, antitumour drugs induce apoptosis through reactive oxygen species (ROS)
generation and altered mitochondrial functions. The evidence presented suggests that yeasts may be a powerful model for the screening/
development of PCD-directed drugs, overcoming the problem of cellular specificity in the design of antitumour drugs, but also enabling the design
of efficient antifungal drugs, targeted to fungal-specific apoptotic regulators that do not have major consequences for human cells.
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Throughout the history of mankind, the quest for drugs with
direct or indirect impact on our well-being and longevity has
been at the cutting edge of human cultural and scientific
development. Medicinal consumption has increased to a new
level in recent decades, fuelling a constant exploration for new
agents that might cure a variety of illnesses, or at least improve
life quality. Infectious diseases and cancers, due to their high
mortality/morbidity rates and impact on human society, have
more recently surfaced as leading target diseases for the design
of effective drugs. Interestingly, most of the antitumour drugs
used nowadays were first selected as antimicrobial agents;
however, after the recognition of their antitumour value, their
characterization substantially increased over the following
years. Additionally, up to date scientific research has pointed
out that the mechanism by which most, if not all, of the
antitumour drugs kill tumour cells involves the induction of cell
death by apoptosis [1]. In fact, the increase in knowledge on⁎ Corresponding author. Tel.: +351 253604812; fax: +351 253604809.
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doi:10.1016/j.bbamcr.2008.01.005programmed cell death (PCD) itself, particularly apoptosis, as
well as its deregulation in tumour cells has dramatically
changed the point of view on the pharmacology of antitumour
drugs. Consequently, great interest has emerged in developing
new strategies that involve the modulation of key molecules that
control life and death decisions, thereby offering an exciting
multitude of molecular targets and therapeutic options for the
future [2,3].
The budding yeast Saccharomyces cerevisiae has been
successfully used as a model organism for the study of mo-
lecular and cellular pathways underlying mammalian diseases.
This is in part due to the high degree of conservation of basic
cellular processes between yeast and higher organisms, as well
as the advantages of yeast genetics [4]. Studies in yeast were the
first to reveal the cellular target of rapamycin, an immunosup-
pressant drug broadly used in human tissue transplants [5,6].
In the last decade compelling evidence accumulated showed
that yeasts are valuable for PCD research due to their ability to
undergo PCD responses which display a certain degree of
conservation with apoptotic mechanisms of higher eukaryotes
[7–9]. Specifically, an apoptosis-inducing factor (AIF1), cyto-
chrome c (cyt c) and HtrA/Omi, that play an important role in
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been identified [8,10–13]. In contrast, no components of the
extrinsic apoptotic regulatory pathway (e.g., death receptors
and their ligands) have been described, showing that yeast cells
do not completely recapitulate the mammalian apoptotic sys-
tem [9]. Molecules involved in mammalian PCD but whose
counterparts are not known in yeast cells such as Bcl-2 proteins
or p53, have been expressed in yeast and studied in more detail
in a genetically tractable system [14–18]. A throughout cha-
racterization of the yeast conserved and non-conserved PCD
regulators and processes may open up new avenues for the
evaluation of drug targets and modes of action. DNA damage
[19] and defects in DNA replication and cell cycle checkpoints
identified in S. cerevisiae [20] have been shown to induce cell
death resembling apoptosis in metazoans, suggesting that future
studies in yeast may provide further valuable input regarding
the complex molecular pathways underlying these events or the
effects of some antitumour drugs directed against those targets.
On the other hand, differences in the architecture of yeast PCD
may allow the targeting of non-conserved genes or gene
products as novel and specific antifungal drug targets to combatTable 1
Overview of the antitumour drugs known to induce apoptosis in yeast and their ass
Apoptosis-inducing antitumour drugs in yeast
Antitumour drugs Apoptotic phenotype
Microtubule-directed
Paclitaxel ROS accumulation
DNA fragmentation
Sub-G0/G1 population
Arrest in G2/M
Miscellaneous
Arsenic DNA fragmentation
Phosphatidylserine exposure
Mitochondrial membrane permeabilization
ROS accumulation
Dependent of metacaspase
Dependent of Tim18p
DNA fragmenting
Bleomycin DNA fragmentation
Chromatin condensation
Sub-G0/G1 population
Independent of mitochondrial function at high concentrations
Histone deacetylase (HDAC) inhibitors
Valproate Dependent of metacaspase
DNA fragmentation
Phosphatidylserine exposure
ROS accumulation
Dependent of Sir2
DNA intercalating
Doxorubicin Mitochondrial dysfunction
Morphological alterations
Phosphatidylcholine (PC) analogues
Edelfosine DNA fragmentation
Mitochondria-derived ROS accumulation
Drugs were divided in classes according to their mode of action. Yeast species/straithe increasing number of fungal infections seen in immuno-
compromised individuals (see related article in this issue).
In this article, we aim to review the evidence on drug-
induced apoptosis in yeast, stressing the overlapping and
distinct elements involved with PCD. To address these issues
we have restricted our review to the most commonly tested
drugs in yeast cells, which are predominantly antitumour and
antifungal drugs.
2. Antitumour drugs
Genetic changes in human tumour cells often include
alterations in the control of cell cycle and/or the regulation of
the cell death process [21]. Therefore, it is not surprising that
most antitumour drugs have, directly or indirectly, apoptotic
regulators as targets. According to their mode of action, such
drugs may be grouped in several different classes, among which
the most relevant promote DNA fragmentation and DNA
intercalation, or are microtubule-directed, histone deacetylase
(HDAC) inhibitors, phosphatidylcholine (PC) analogues/inhi-
bitors, topoisomerase inhibitors or antimetabolites. Variousociated apoptotic phenotypes
Yeast species References References of apoptosis in
mammals
Saccharomyces cerevisiae AD1-8-tax [32] [25–28]
Saccharomyces cerevisiae BY4742 [39,40] [36–38,41]
Saccharomyces cerevisiae YHP-1 [50] [48,49]
Saccharomyces cerevisiae W303-1A [57,58] [52,53,56]
Candida utilis ATCC 8205 [64] [62,63]
Saccharomyces cerevisiae BY4742 [73] [65]
ns used in the different studies are listed.
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mechanism of action and, representative agents of each of these
classes have been shown to induce an apoptotic phenotype
(Table 1). However, some antitumour drugs studied in yeast
have not been assigned as inducers of PCD, e.g. farnesol,
fredericamycin A, camptothecin, etoposide, 5-fluorouracil, sel-
enium, coumarin, and 1,10-phenanthroline. This may be for
many reasons, including lack of experiments that directly
characterize cell death. Given that, the cytotoxic phenotype
and the molecular context of their action are in many cases
related to the triggering of a PCD process (Table 2), they will
also be covered in this review.
2.1. Apoptosis-inducing antitumour drugs in yeast
Paclitaxel, arsenic, bleomycin and valproate (VPA) represent
the most well studied antitumour drugs inducing yeast apoptotic
phenotypes (Table 1; Fig. 1). Paclitaxel is a complex diterpene
that was initially isolated from the bark of the Pacific yew tree
Taxus brevifolia [22] and has subsequently been shown to be a
fungal metabolite [23]. In mammalian cells, paclitaxel has been
shown to bind to β-tubulin, disturbing the equilibrium between
the soluble and polymeric forms of tubulin [24], leading to
cell cycle arrest at G2/M phases and induction of apoptosis in
proliferating cells [25,26]. Paclitaxel has been shown to induceTable 2
Overview of the antitumour drugs inducing cytotoxicity in yeast cells
Cytotoxicity of antitumour drugs in yeast
Antitumour
drugs
Phenotype Yeast species
Phosphatidylcholine (PC) inhibitors
Farnesol Growth arrest Saccharomyces cerevisiae
ROS accumulation
Repression of cell cycle genes
(CDC9; HAT2)
Topoisomerases inhibitors
Fredericamycin
A
Arrest in G1 Saccharomyces cerevisiae
ROS accumulation
Aberrant mitochondria
Camptothecin Arrest in G2/M Saccharomyces cerevisiae
DNA damage
Etoposide Arrest in G2/M Saccharomyces cerevisiae
Antimetabolites
5-Fluorouracil Inhibition of growth Saccharomyces cerevisia
Clinical isolateArrest in G1/S
Miscellaneous
Selenium Toxicity exacerbated by glutathione Saccharomyces cerevisiae
Toxicity exacerbated by thiols
Formation of Hydrogen Selenide
Coumarin ROS accumulation Candida albicans ATCC
Nuclear dysfunctions
Loss of membrane organelles
1,10-
Phenanthroline
DNA degradation Candida albicans ATCC
Nuclear dysfunctions
Mitochondrial
function disruption
Drugs were divided in classes according to their mode of action. Yeast species/straiphosphorylation of the anti-apoptotic protein Bcl-2 [27] and, at
least in vitro, FAS-associated death domain protein (FADD)-
dependent apoptosis through activation of caspase-10 [28].
Growth of wild-type yeast cells is not inhibited by paclitaxel,
due, most probably, to the differences between yeast and mam-
malian tubulin residues involved in paclitaxel binding [29–31].
However, mutations in the yeast β-tubulin promote the accu-
mulation of intracellular reactive oxygen species (ROS), DNA
fragmentation (detected by terminal dUTP nick-end labeling
(TUNEL) assay), and alterations of the cell cycle profile (Fig. 1)
characterized by an arrest in the G2/M phases and the ap-
pearance of a sub-G0/G1 population [32], consistently with a
mitotic blockage as described in mammalian cells [33,34].
Studies with paclitaxel also exemplify how the problem of drug
extrusion by yeast (seen as a main constraint in yeast use for
antitumour drug target characterization) can be overcome by the
modulation of multidrug ABC transporters, thereby facilitating
the accumulation of the drug in yeast cells [32].
Arsenic, a highly toxicmetalloid, has been used in a variety of
ways over the past 200 years not least as an extremely potent
anti-leukemic agent [35]. Cytotoxicity studies have shown
that chronic arsenic exposure induces profound cellular altera-
tions including apoptosis characterized by ROS accumulation,
mitochondrial aggregation, Bax oligomerization, mitochondrial
membrane potential (Δψm) dissipation and caspase activationReferences References of apoptosis in
mammals
X2180-1A [78,79] [74,162]
W303-1A [87] [82]
FY250/FY251 [88] [86]
JN362acc [89] [84]
e BY4741/BY4742 Candida albicans [92,96,97] [163]
DTY7 [93] [164]
10231 [94] [98]
10231 [95] [95,99]
ns used in the different studies are listed.
Fig. 1. Schematic representation of yeast apoptotic phenotypes and events induced by antitumour drugs. ROS appears to possess, like in mammalian cells, a central role
in the induction/signalling of yeast apoptotic process, with paclitaxel, valproate, arsenic and edelfosine leading to their generation/accumulation. ROS production
during edelfosine-induced apoptosis has been demonstrated to be mitochondria-dependent. The crucial involvement of mitochondria on antitumour drug-induced
apoptosis is clearly reflected during arsenic-induced apoptosis, with mitochondria suffering a decrease in membrane potential (Δψm) and with the requirement of
Tim18p, a mitochondrial translocase located in mitochondrial inner membrane (IM), to act downstream ROS. In addition, mitochondria were described as the targets
of doxorubicin. Yeast metacaspase, Yca1p, was also necessary for the execution of apoptosis induced by both arsenic and valproate. Of note, valproate displays a dual
effect on yeast cells, with high concentrations inducing cell death with characteristics similar to those of ACD and low concentrations inducing Sir2p-dependent
apoptosis. All antitumour drugs seem to induce yeast DNA fragmentation with the exception of doxorubicin where this apoptotic feature was not assessed. The
apoptotic events triggered by antitumour drugs are represented by arrows displaying a specific colour for each drug: paclitaxel (brown), valproate (gray), bleomycin
(purple), edelfosine (blue), arsenic (red) and doxorubicin (green). Black arrows indicate already known yeast apoptotic events.
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from isolated liver mitochondria via the mitochondrial perme-
ability transition pore [37,38]. In contrast to paclitaxel, arsenic
can exert its toxic effects and trigger apoptosis in wild-type
S. cerevisiae cells. Recently, arsenic was shown to induce
DNA fragmentation, phosphatidylserine exposure, mitochon-
drial membrane permeabilization and ROS accumulation in
S. cerevisiae cells [39,40] (Fig. 1). The arsenic resistant phe-
notype of rho0 mutant cells, as well as the decrease of DNA
fragmentation and cell death in metacaspase (Yca1p) mutant
cells supports the involvement of both mitochondria and
Yca1p in the cell death process [39]. In addition, Tim18p, a
component of the mitochondrial translocator, was implicated as
a mediator of arsenic-induced yeast apoptosis, acting down-
stream of ROS production (Fig. 1) [40]. The deletion of CuZn
superoxide dismutase (SOD) also enhances arsenic's toxic
effects, further indicating that ROS play an important role in
this process [39], in accordancewith recent findings by Seok et al.
in a zebrafish liver cell line [41]. Arsenic reacts with sulphurcontaining compounds, such as glutathione (GSH) or cysteine
acting as a potent inhibitor of GSH reductase and thioredoxin
reductase [42], thereby increasing cellular oxidation levels.
Bleomycin, a compound isolated from Streptomyces verti-
cillis [43,44] is primarily used as an antibiotic and is also
employed clinically in cancer therapy due to its ability to induce
single-strand and double-strand DNA breaks [45,46]. Although
not yet characterized, a receptor protein mediating bleomy-
cin internalization has been suggested to exist on the plasma
membrane of both mammalian and yeast cells [47]. Upon
entering a cell, bleomycin induces cell death through a JNK-
dependent mitochondrial death pathway in alveolar epithelial
cells [48], and causes apoptosis in lung epithelial cells by
increasing ROS generation/accumulation and mitochondrial
leakage, which require the participation of caspase-8 and -9, and
the Fas/FasL pathway [49]. Bleomycin-induced apoptotic
cell death in yeast (Fig. 1) is mainly characterized by the
appearance of a sub-G0/G1 population, the generation of DNA
double-strand breaks, and, at high bleomycin concentrations,
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[50].
Similar to other antitumour drugs, VPA, an inhibitor of the
class I HDACs [51] can trigger apoptosis in mammalian cells
through caspase-dependent and -independent pathways [52,53].
VPA also promotes the down-regulation of pro-survival genes,
Bcl-2 and Bcl-XL, and the up-regulation of pro-apoptotic genes
such as Bax [54,55]. A recent study also demonstrates that VPA
induces caspase-dependent apoptosis in HeLa cells through the
blocking of the Akt pathway [56]. Likewise, in yeast cells, VPA
triggers a cell death process that is dependent on Yca1p [57]
(Fig. 1). Exposure to high concentrations of VPA induces cell
death with morphological features similar to those of autopha-
gic cell death (ACD), which is independent of Yca1p [57],
while low VPA concentrations result in apoptotic cell death
associated with DNA fragmentation, ROS accumulation,
phosphatidylserine exposure and morphological alterations
such as cell shrinkage [57,58]. Sun et al. showed that Sir2p or
sirtuin, a class III HDAC, that is also involved in the DNA
damage response and life span extension mediated by caloric
restriction [59,60], is required for VPA-induced cell death [58].
Accordingly, Δsir2 cells do not produce ROS or accumulate
neutral lipids, leading to the conclusion that Sir2p has a role in
lipid metabolism, which might be linked to apoptosis [58].
Other antitumour drugs presented in Table 1 and described
as inducing apoptosis in yeast cells include doxorubicin (DOX)
and edelfosine. DOX is an antibiotic, originally isolated from
Streptomyces peucetius and currently used as an effective an-
titumour drug [61] known to induce, among other events, the
generation of free radicals, DNA damage and apoptosis, via an
inhibition of topoisomerase II [62,63]. In yeast, DOX was
shown to induce apoptosis in Candida utilis, based merely upon
morphological observations, with reported plasma membrane
alterations and changes in mitochondrial shape and cristae
organization [64] (Fig. 1). Therefore, further studies directed to
known yeast apoptotic regulators are needed in order to uncover
the mechanism by which DOX kills yeast cells.
Edelfosine is a synthetic lipid, analogue of phosphatidylcho-
line (PC), which induces apoptosis in a wide variety of tumour
cells [65]. Edelfosine and its analogues contain ether linked fatty
acids, as opposed to the endogenous ester linked fatty acids,
rendering them more resistant to cellular phospholipases and,
thus, more effective as drugs. Although not as an amplificatory
mechanism, like bleomycin [49], edelfosine was found to induce
Fas-dependent apoptosis in leukemic cells [66]. Overexpression
of Bcl-2 or Bcl-XL was shown to be able to inhibit apoptosis
induced by this compound [65,67], which was also shown to be
associated with alterations in mitochondrial function, generation
of ROS and caspase-3 activation [68,69]. Recently it was
suggested that endoplasmic reticulum may also play a major
role in edelfosine-induced apoptosis in tumour cells [70]. In
addition to its cytotoxic effects [71,72], edelfosine was reported
to promote apoptosis in S. cerevisiae cells characterized by a
TUNEL-positive phenotype and mitochondrial dependent ROS
generation [73], presenting similarities with edelfosine-induced
apoptosis in human tumour cells, also mediated by mitochon-
dria and correlated with ROS generation [68,69].The accumulated evidence indicates that the mechanisms of
antitumour drug-induced apoptosis in yeast share some homo-
logies with the mammalian system. Particularly predominant
are the involvement of mitochondria, DNA fragmentation, and
especially ROS production/accumulation. Nevertheless, not all
the studies regarding the induction of apoptosis in yeast cells by
antitumour drugs explore the knowledge of yeast molecular
PCD pathway(s), namely, the precise association of the apop-
totic regulators and their hierarchy. Even so, the data herein
presented point out the potential value of yeast to study PCD-
based therapies and drug targets.
2.2. Cytotoxicity of antitumour drugs in yeast
As a model organism, yeast has long been used as a phar-
macological tool in the identification and definition of the
molecular context and of critical determinants that confer
chemosensitivity to specific cytotoxic injuries induced by drugs.
Several of the different antitumour drugs studied in yeast have
not been specifically assigned as inducers of PCD, although,
the cytotoxic phenotype and the molecular context of their
action are suggestive of that. Drugs such as the PC inhibitor
farnesol and some topoisomerases inhibitors are worth of further
discussion (Table 2). Farnesol is known to induce apoptosis in a
wide variety of cell lines [74,75]. Farnesol-induced cell death is
attenuated through the addition of exogenous PC or diacylgly-
cerol, but not other lipids [76,77]. In yeast cells, farnesol has
been shown to induce growth arrest and cell death, with
repression of cell cycle genes encoding a DNA ligase (CDC9)
and a histone acetyltransferase (HAT2), a process that can be
inhibited by the addition of a diacylglycerol analogue [78].
Although farnesol induces the generation of ROS [79,80], the
farnesol-induced cell death mechanism remains uncharacterized
in yeast cells. Nevertheless, farnesol has been described to
induce apoptosis in Aspergillus nidulans cells characterized by
chromatin condensation, a TUNEL-positive phenotype, expo-
sure of phosphatidylserine, and is also dependent on mitochon-
drial function and ROS generation [81].
Other successful antitumour drugs take advantage of the
inhibition of topoisomerases, key enzymes in DNA transcription
and replication. Fredericamycin A (FMA), an antibiotic product
of Streptomyces griseus, camptothecin, an alkaloid derived from
the plant Camptotheca acuminate and etoposide, a derivative of
the podophyllotoxin from Podophyllum peltatum are among the
antitumour drugs known to induce apoptosis in mammalian cells
due to the inhibition of topoisomerases [82–86]. Although the
induction of apoptosis in yeast cells by those drugs is not
supported by the available data, some lines of evidence do
support a link. For example, FMAwas shown to induce growth
arrest (G1 cell cycle phase) and the appearance of aberrant
mitochondria in yeast, just as in mammalian cells, which also
results in the generation of high intracellular ROS levels [87].
Furthermore, and even though evidence for apoptosis induced
by etoposide and camptothecin in yeast cells is scarce, these
topoisomerase inhibitors are known to induce arrest in the G2/M
cell cycle phases and DNA damage [88,89], a phenomenon also
observed in other drugs inducing apoptosis in yeast [90,91].
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coumarin and 1,10-phenanthroline, have been described as cy-
totoxic agents that lead to yeast cell death [92–97]. However,
the mechanism of the cell death process underlying their
cytotoxicity remains unexplored. Nonetheless, treatment with
coumarin and 1,10-phenanthroline stimulates ROS genera-
tion, changes in nuclear morphology and a loss of membrane
organelles [94,95], indicating that apoptotic cell death might
take place in yeast as demonstrated in mammalian cells [98,99].
Future studies directed towards the identification of the true
nature of the cell death processes that occur upon treatment
with these drugs will bring forth important data regarding drug-
induced apoptotic phenotype in yeast strengthening its claim as
a useful tool for screening the cytotoxic effects of antitumour
drugs.
3. Apoptosis-inducing antifungal drugs in yeast
S. cerevisiae represents a practical and conventional system
for studying the properties of antifungal compounds, not only
against fungal human pathogens with which they are closely
related (e.g., Candida albicans) [100], but also with those that
are evolutionarily more distant (e.g., filamentous fungi). More-
over, the majority of the currently used antifungal drugs are
active against S. cerevisiae (reviewed in [101]), thus making it a
suitable model for both drug development and the elucidation of
the mechanisms underlying drug's action.Most antifungal drugs
belong to a few structural classes that affect specific fungal
cellular targets, such as ergosterol synthesis. However, many of
these drugs are associated with a high human toxicity (e.g.
amphotericin B) and/or to the selection of resistant fungal pa-
thogens (e.g., azole drugs), two main constraints on the success
of antifungal drug therapies. To overcome the changing tide of
fungal diseases, novel fungal targets for drug therapy need to
be identified. As described above, the possible architectural
differences between apoptotic regulators/mechanisms of yeast
and mammalian cells may open the door either for the design
of new antifungal drugs, or for testing the fungal-specific
apoptotic-inducing abilities of the current ones. In fact, some
drugs with known antifungal capacities have already been
demonstrated to act as yeast-specific apoptotic PCD-inducers
(Table 3). Among these, some are currently used in clinics while
others are still under development. One of the best characterized
and commercially available antifungal drugs is amphotericin B
(AmB), a polyene agent efficiently used for treating invasive
fungal infections, but generally associated with high toxicity
against human cells [102]. AmB binds to sterols, creating pores
that increase fungal membrane permeability to small cations,
thus promoting the rapid depletion of intracellular potassium and
fungal cell death [103]. Phillips et al. assessed the toxic effects
of AmB inC. albicans, revealing that AmB induces an apoptotic
mechanism, with the occurrence of arrest in G2/M cell cycle
phases, chromatin condensation, nuclear fragmentation, phos-
phatidylserine externalization and ROS accumulation [91].
Ciclopirox olamine (CPO), a representative of a quite distinct
class of antifungal drugs, was introduced into clinical therapy
more than three decades ago. CPO belongs to a group of syn-thetic antifungal agents, hydroxypyridones that have high af-
finity for trivalent metal cations [104], that are used effectively
in clinical practice since they have a broad spectrum of action
against dermatophytes, yeasts, filamentous fungi and bacteria
[105]. A remarkable feature of CPO is that no single case of
fungal resistance has been reported so far. Work performed by
our group has shown that CPO leads to non-apoptotic yeast PCD
characterized by chromatin condensation and DNA damage
associated with the appearance of a sub-G0/G1 population and
arrest in G2/M cell cycle phases [90]. Notably, in contrast to
AmB-induced apoptosis, CPO-induced PCD does not involve
ROS signalling and is associated with a TUNEL-negative
phenotype; CPO-induced PCD also appears to be independent of
metacaspase but is associated with unknown protease activities
[90].
Besides the described antifungal drugs, other compounds
isolated from distinct organisms have proved to display effective
antifungal capacities through the induction of apoptosis. Os-
motin, a Tobacco pathogenesis-related protein, dermaseptins, a
family of peptides derived from the tree-frog Phyllomedusa
sauvagii, and pradimicin (PRM), an Actinomadura hibisca-
derived antibiotic, were found to induce cell death in yeast with
apoptotic features [106–109]. All of these drugs were shown to
induce nuclear fragmentation, a TUNEL-positive phenotype and
the generation of high intracellular ROS levels [106–109].
However, some differences were detected among the apoptotic
cell death processes triggered by these drugs. The mechanism by
which osmotin induces apoptosis, relies on the suppression of
stress-responsive gene transcription via the RAS2/cAMP path-
way, and, upstream from RAS2, on the binding of osmotin to
the plasma membrane protein Pho36, a homologue of the mam-
malian receptor for the hormone adiponectin [106,110]. On the
other hand, the truncated derivative of dermaseptin S3 [111],
which promotes disruption of the yeast cell membrane and a
deregulation in the homeostasis of intracellular pH, was shown
to induce S. cerevisiae PCD associated with ROS generation and
nuclear DNA fragmentation [107,108]. Interestingly, the mode
of dermaseptin-induced cell death is metacaspase-independent,
but dependent on Aif1p, and on the proteasomal substrate,
Stm1p [108], which is also involved in yeast apoptosis [112]. In
addition to their capacity to induce yeast apoptosis, dermaseptins
have very low human cytotoxicity. In fact, the same is true for
most of the naturally occurring antimicrobial peptides from
amphibian skin, at concentrations that effectively inhibit fungal
growth [111,113–115], making them very attractive antifungal
drugs. PRM, a mannose-binding antifungal antibiotic that cau-
ses membrane permeability dysfunction, is also capable of
inducing S. cerevisiae apoptotic cell death, characterized by
ROS accumulation, DNA damage and nuclear fragmentation
[109]. The cell death mechanism seems to be dependent on the
sensor kinase, Sln1p, to which PRM can bind [116].
Another group of compounds that display antifungal capa-
cities are histatins, histidine-rich cationic peptides secreted by
the parotid and the submandibular/sublingual human salivary
glands [117]. Histatin 5 has been shown to display potent fun-
gicidal properties against C. albicans [117]. Although scarce,
evidence for the induction of a histatin 5-mediated apoptotic
Table 3
Overview of the antifungal drugs known to induce apoptosis in yeast and their associated apoptotic phenotypes
Apoptosis-inducing antifungal drugs in yeast
Antifungal drugs Apoptotic phenotype Yeast species References References of apoptosis in mammals
Cell permeability disruptor
Amphotericin B Arrest in G2/M Candida albicans CaF-2 [91] [102]
Chromatin condensation
Nuclear fragmentation
Phosphatidylserine externalization
ROS accumulation
Metal cation chelator
Ciclopirox
olamine
Chromatin condensation Saccharomyces cerevisiae BY4742 [90] –
Sub-G0/G1 population
Arrest in G2/M
Nuclear dysfunction
Independent of ROS accumulation
Independent of metacaspase
Associated with unknown protease(s)
Plasma membrane binders/disruptors
Osmotin DNA fragmentation Saccharomyces cerevisiae BWG7a [106,110] –
ROS accumulation
Dependent on the suppression of transcription of
stress-responsive genes via RAS2/cAMP pathway
Dependent on the binding to Pho36p
Dermaseptin DNA fragmentation Candida albicans IP886-65
Saccharomyces cerevisiae BY4742
[107,108,111] –
ROS accumulation
Metacaspase independent
Dependent of the apoptosis-inducing factor
(Aif1p) and the proteosomal substrate (Stm1p)
Pradimicin DNA fragmentation Saccharomyces cerevisiae 953 [109,116] [165,166]
ROS accumulation
Dependent of the sensor kinase, Sln1p
Mitochondrial membrane disruptor
Histatin Mitochondrial membrane depolarization Candida albicans 10S DS1
31531A
[118–122] –
Mitochondrial swelling
Loss of intracellular ATP and amino acids
Arrest in G1
ROS accumulation
Drugs were divided in classes according to their mode of action. Yeast species/strains used in the different studies are listed.
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results in mitochondrial membrane depolarization and mito-
chondrial swelling, loss of intracellular ATP and amino acids,
cell cycle arrest in G1 phase and the generation of ROS, although
this latter feature still remains controversial [118–122]. Veerman
et al. state that ROS do not play a role in the histatin 5-mediated
death of C. albicans cells since no effect on survival was ob-
served using the ROS scavenger Tempo (2,2,6,6-tetramethylpi-
peridine-N-oxil) [123]. New studies on the effects of histatin 5
on yeast cells, especially on those focused on the involvement of
known apoptotic regulators, may uncover its cell death-inducing
mechanism of action.
It is conceivable that the capacity of AmB to trigger yeast
apoptotic-PCD underlies its high fungicidal activity. Indeed,
AmB also triggers apoptosis in human cells which might
explain its high cytotoxicity [102]. Therefore, the design of new
antifungal drugs should consider the less evolutionary con-
served steps and focus on the yeast-specific regulators of PCD.Natural compounds isolated from diverse organisms, includ-
ing humans, are assuming great importance since they possess
high antifungal activity and low human toxicity. Interestingly, as
described above, most seem to induce apoptosis in yeast
revealing that they are potentially targeting fungal-specific cell
death pathways and/or regulators. Thereby, the elucidation of
unique fungal PCD pathways/regulators would revolutionize the
manner in which antifungal drugs are designed.
4. Other drugs inducing apoptosis in yeast
Besides exploiting yeasts in the study of the mode of action
of antitumour and antifungal drugs, yeasts have also been used
to ascertain the cytotoxicity of many different drug types. In
many cases these drugs also have certain antitumour properties
although they are not usually used for this purpose. For this
review we have selected two such drugs, (i) aspirin, one of the
World's safest and least expensive pain relievers with over
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ailments, and (ii) ricin, a toxin isolated from plants that has the
capacity to inhibit protein synthesis by irreversibly inactivating
eukaryotic ribosomes.
Aspirin, or acetylsalicylic acid, is a non-steroidal anti-
inflammatory drug known to induce apoptosis in mammalian
cells by a variety of different mechanisms including caspase
activation [124,125], inhibition of NF-KB activation [126], ce-
ramide pathway activation [127] and p38MAP kinase activation
[128]. The effects of aspirin on cell growth and its propensity to
induce apoptosis have also been studied in yeast cells. Aspi-
rin was found to commit mitochondrial MnSOD-deficient
S. cerevisiae cells growing in ethanol to apoptosis [129]. In
accordance with aspirin's ROS scavenger properties, it also
exhibits a significant antioxidant effect until the onset of overt
apoptosis in yeast cells, suggesting that ROS probably do not
play a primary role in the apoptosis of cells exposed to aspirin
[129]. Instead, the authors suggest that a disruption of the redox
balance commits yeast cells to apoptosis upon aspirin treatment
[130].
Ricin is naturally synthesized in the seeds of Ricinus com-
munis (castor bean). This plant toxin is a type II ribosome-
inactivating protein (RIP) that inhibits protein synthesis [131].
It consists of a catalytic A chain (RTA) covalently joined by a
disulfide bond to a cell binding B chain (RTB) and is highly toxic
to eukaryotic cells [132,133]. The RTB is a lectin that binds
galactose or N-acetylgalactosamine receptors on the surface of
target cells and promotes subsequent endocytosis of the RTA
[132,133]. Ricin induces apoptosis in a wide variety of animal
cells [134] and recently the effects of ricin were studied in
S. cerevisiae, using a large-scale mutagenesis screen for variants
of the precursor form of RTA (pre-RTA) that were unable to kill
yeast cells. Apoptotic markers, such as chromatin condensation,
nuclear fragmentation and ROS accumulation were observed
for yeast cells expressing the wild-type RTA but not for cells
expressing the nontoxic mutants, even though they still de-
purinated ribosomes and inhibited translation [135]. These re-
sults provide evidence showing that similar to the studies in
mammalian cells, ribosome depurination and translation inhibi-
tion are also not sufficient for the ricin-induced cytotoxicity in
S. cerevisiae. Moreover, the mechanism of apoptotic cell death
seems to be strictly dependent on the early generation of ROS
[135].
5. Conclusions and future perspectives
The field of yeast PCD, particularly apoptotic-PCD, has
grown rapidly during the last decade [7–9]. The increasing
understanding of yeast PCDmolecular pathways is crucial either
for the basic knowledge or for the application of this knowledge
to the use of yeasts as a model for cell death-based therapies.
Yeasts have been intensively explored to study a wide range of
processes, from the basic cellular and molecular pathways to
the implications of their regulation and dysfunction in human
diseases. Previously, yeast cells containing mutations in genes
associated with a specific disease, e.g. tumour associated alte-
rations in DNA repair, mitotic catastrophe, etc., have allowed thescreening of drugs that kill mutant cells more efficiently than
wild-type cells [136,137]. These strategies have been used
successfully revealing several antitumour agents with a high
therapeutic advantage [138,139]. The power of yeast molecular
genetics, including the multi-faceted role of yeast in drug
discovery is also apparent from yeast two-hybrid and three-
hybrid systems that have been employed in target identification
and validation; the yeast target-based screenings such as high-
throughput screening or cell based assays; phenotype-based
screening; gene expression profiling of drug action and drug-
induced haploinsufficiency (reviewed in [101,140,141]). There-
fore, one may already consider “Yeast as a model in drug target
discovery and validation”. The question that now arises is, can
we now reasonably say that “Yeasts are also a good model in
apoptosis or cell death-based therapies and drug targets”? The
examples addressed in this review show that some therapeutic
agents induce yeast apoptotic-PCD that certainly have some
similarities with the cell death processes known in mammalian
cells. For most of the cell death scenarios induced by antitumour
drugs and discussed herein, ROS and mitochondria appear as
crucial yeast and mammalian players. This evidence brings us to
a relevant and recurrent theme in tumours and chemotherapy:
mitochondria and ROS as therapeutic targets. Indeed, a great
variety of drugs can directly be targeted to mitochondria to
induce apoptosis [142] or to ROS scavenging, resulting in ROS
accumulation and apoptosis (reviewed in [143,144]). Besides
ROS, nitric oxide (NO), which reacts with molecular oxygen to
form reactive nitrogen species (RNS) and ultimately favours
carcinogenesis [145], is also an appealing target. Somewhat
paradoxically, both anti-NO and NO-based strategies have been
applied in cancer therapy (reviewed in [145,146]) indicating a
NO dichotomy and an inevitable need of modulate NO levels
according to the specific molecular makeup of each individual
tumour cell (reviewed in [145,146]). Recently, we demonstrated
that S. cerevisiae is able to synthesize NO by an L-arginine-
dependent mechanism, controlling the formation of ROS and
acting as a crucial apoptotic inducer [147,148]. Following this
line of thought, yeast could be employed in the study of the
synergistic effects as well as molecular pathways that determine
the increased sensitivity of cells to antitumour drugs in the
presence of different endogenous NO levels.
Other cellular processes that have been revealed as future
therapeutic targets include the proteasome, Heat Shock Protein
90 (HSP90), and non-apoptotic PCD pathways including ACD,
all of which could be explored using yeast. Yeast proteasome
function has already been linked to apoptotic cell death [112]. As
the proteasome is a critical enzymatic complex for fundamental
pathways in cell survival and proliferation, its inhibition could
be a potential antitumour therapy [149,150]. The established
link between proteasome and yeast apoptosis suggests that a
proteasome inhibition-based therapy could also be investigated
in yeast.
The molecular chaperone HSP90, required to ensure the cor-
rect conformation, activity, intracellular localization, and proteo-
lytic turnover of a range of proteins that are involved in cell
growth, differentiation, and survival [151,152], is also an at-
tractive target for tumour therapy. It is already known that
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called “client proteins”, which are reported to be involved in
tumourigenesis [151], via the ubiquitin-proteasome pathway
[153,154]. Interestingly, our recent observations point to a
protective role of HSP90 members in yeast apoptosis (Almeida,
B. et al., unpublished data). Using yeast to assess for HSP90
“client proteins”, upon treatment with HSP90 inhibitors, could
easily contribute to the understanding of its mode of action
and role in tumourigenesis. Regarding non-apoptotic PCD
process such as ACD, accumulated evidence has shown that
this phenomenon also occurs in yeast cells [155–157]. Since
many reports show that antitumour drug-induced cell death
may involve non-apoptotic PCD through caspase-independent
pathways [158,159] or even through the induction of ACD [160],
the yeast system seems promising for revealing clues on the
foundation of new opportunities to design targeting therapy to
promote non-apoptotic cell death of tumour cells.
An interesting link between HSPs, the proteasome and
autophagy relates to the fact that they all act as cellular defenses
in neurodegenerative disorders, especially those that involve
protein misfolding. Given the fact that yeast is being used as a
model to study several neurodegenerative disorders involving
protein misfolding and aggregation [161], it seems feasible to
also use yeast for screening of drugs that are able to increase
survival by acting on these targets.
Although yeast cells are useful for the study of the cytotoxic
effects of a panoply of drugs, their primary relevance might be
directed to the design of new antifungal drugs. A new
generation of antifungal drugs is urgently needed given the
problems associated with ones currently in use and to the
increasing number of invasive fungal infections in immuno-
compromised patients. In this sense, the exploration of yeast
PCD processes to identify molecules that allow the specific
manipulation of yeast cell death without causing serious side
effects on human cells is appealing. Until recently the
cumulative knowledge on yeast PCD shows a high conservation
of cell death processes and regulators, however substantial
differences will necessarily be detected among molecules and/
or pathways as the field develops. One good example is the
fungal metacaspases which seem to be the main executors of a
wide range of apoptotic stimuli. Even though metacaspases are
orthologs of caspases, they display enough structural dissim-
ilarity to allow the design/screening of compounds or molecules
that selectively activate metacaspases and not caspases. For this
to be possible more effort needs to be applied to the study of
yeast PCD.
On the other hand, we must not disregard the existence of
distinct cellular machineries linked to yeast PCD induction that
may be relevant as future therapeutic targets. In fact, one of the
main problems regarding the design of antitumour drugs is the
cellular specificity; ergo, some drugs are effective only against a
particular kind of tumour cells while ineffective for others. As
simple eukaryotic microorganisms with less complex PCD re-
gulation without the idiosyncrasies of different cell types, yeasts
are undoubtedly important models for the design of therapies
directed to basic molecular pathways, thus overcoming the
problem of cellular specificity.The examples presented throughout this review show in
very distinct ways the real utility of yeasts in drug-induced cell
death discovery. In addition, the plethora of tools available,
along with our knowledge of PCD also makes yeast a highly
valuable model organism for drug target identification and
validation. Future studies are required in order to fully cha-
racterize the “ups and downs” of yeast PCD and definitively
expose the extent of potential benefits that yeast may present to
study these issues.
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